Transaction Details

Footnotes

The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 18, 2025. | The options vested with respect to 1/4 of such shares on March 6, 2024, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. | The options vested with respect to 1/4 of such shares on March 4, 2023, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. | The options vested with respect to 1/4 of such shares on April 19, 2018, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. | The options vested with respect to 1/4 of such shares on November 1, 2018, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. | The options vested with respect to 1/4 of such shares on October 1, 2019, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. | The options vested with respect to 1/4 of such shares on January 1, 2020, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. | The options vested with respect to 1/4 of such shares on March 4, 2025, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. | The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.50 to $16.90, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. | The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.50 to $17.44, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.